Nikolas K. Haass

Nikolas K. Haass

The Centenary Institute

Affiliated withThe Centenary InstituteThe University of QueenslandUniversity of Sydney

Research Area

Biography

Nikolas Haass, MD/PhD/FACD

Professor for Cutaneous Oncology/Principal Research Fellow

Head, Experimental Melanoma Therapy Group

Director of Higher Degree Research UQDI

Academic lead of TRI’s Microscopy Facility

Nikolas Haass is a clinician scientist and academic leader with research in melanoma cell biology and experimental melanoma therapy. He received his degree in medicine from the University of Heidelberg, Germany (1990-1998). He graduated summa cum laude with a PhD in Cell Biology from the University of Heidelberg (1993-1999) and trained in clinical dermatology at the University of Hamburg, Germany (1999-2003). In 2003 he moved to Philadelphia, PA, to work as a post-doctoral fellow in Meenhard Herlyn’s lab at The Wistar Institute/University of Pennsylvania (2003-2007). From there he was recruited as an associate faculty member to the Centenary Institute/University of Sydney (2007-2013). In 2013 he commenced a position as Professor for Cutaneous Oncology at University of Queensland Diamantina Institute.

Using cutting-edge technology, including real-time cell cycle imaging in 3D culture and in vivo, his team studies the role of dynamic melanoma heterogeneity in melanomagenesis with the goal to develop novel therapeutic approaches by simultaneously targeting different tumor cell subpopulations. His laboratory and his team are in the unique position to combine sophisticated imaging and biosensor approaches with biochemical methods to provide unprecedented insight to the mechanisms of tumor heterogeneity, tumor-stroma interactions and cancer immunology.

JoVE Journal Publications

ArticleTotal : 2
Year
Imaging- and Flow Cytometry-based Analysis of Cell Position and the Cell Cycle in 3D Melanoma Spheroids
Publication title

Cited by 57

2015
2022

Other Publications

Article
Year
The role of altered cell-cell communication in melanoma progression.

Journal of molecular histology| PubMed ID: 15339050

2004
2005
Adhesion, migration and communication in melanocytes and melanoma.

Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society| PubMed ID: 15892711

2005
Differential induction of connexins 26 and 30 in skin tumors and their adjacent epidermis.

The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society| PubMed ID: 16046668

2006
Normal human melanocyte homeostasis as a paradigm for understanding melanoma.

The journal of investigative dermatology. Symposium proceedings / the Society for Investigative Dermatology, Inc. [and] European Society for Dermatological Research| PubMed ID: 16358819

2005
2006
2007
Expression of integrin alpha10 is induced in malignant melanoma.

Cellular oncology : the official journal of the International Society for Cellular Oncology| PubMed ID: 17726260

2007
2008
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Proceedings of the National Academy of Sciences of the United States of America| PubMed ID: 18287029

2008
2008
2009
2010
Genetics of basal cell carcinoma.

The Australasian journal of dermatology| PubMed ID: 20546211

2010
2010
2010
2011
Meeting report from the 2011 International Melanoma Congress, Tampa, Florida.

Pigment cell & melanoma research| PubMed ID: 22117673

2012
Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.

Clinical cancer research : an official journal of the American Association for Cancer Research| PubMed ID: 22173547

2012
2013
2008
2013
2013
2013
Targeting glutamine transport to suppress melanoma cell growth.

International journal of cancer. Journal international du cancer| PubMed ID: 24531984

2014
Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy.

Pigment cell & melanoma research| PubMed ID: 24655414

2014
Melanoma never says die.

Experimental dermatology| PubMed ID: 24684560

2014
2014
2014
Friends or foes: IL-10 and TGF-β in melanoma.

Experimental dermatology| PubMed ID: 25661188

2015
2015
2015
2015
Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells.

The Journal of investigative dermatology| PubMed ID: 26970356

2016
2016
Modeling Melanoma In Vitro and In Vivo.

Healthcare (Basel, Switzerland)| PubMed ID: 27429258

2013
Multimodal tumor suppression by miR-302 cluster in melanoma and colon cancer.

The international journal of biochemistry & cell biology| PubMed ID: 27840154

2016
2016
2017
2017
2017
2017
Real-Time Cell Cycle Imaging in a 3D Cell Culture Model of Melanoma.

Methods in molecular biology (Clifton, N.J.)| PubMed ID: 28634959

2017
Acetylsalicylic Acid Governs the Effect of Sorafenib in -Mutant Cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research| PubMed ID: 29196297

2018
2018
Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors .

Clinical cancer research : an official journal of the American Association for Cancer Research| PubMed ID: 29535131

2018
2018
2018
2018
2014
2015
2018
2019
2019
2019
2019
2019
2020
2020
2021
2020
2021
A novel mathematical model of heterogeneous cell proliferation.

Journal of mathematical biology| PubMed ID: 33712945

2021
Rapid initiation of cell cycle reentry processes protects neurons from amyloid-β toxicity.

Proceedings of the National Academy of Sciences of the United States of America| PubMed ID: 33737393

2021
2021
2021
2021
2021
2022
PTEN: A novel target for vitamin D in melanoma.

The Journal of steroid biochemistry and molecular biology| PubMed ID: 35033661

2022
Designing and interpreting 4D tumour spheroid experiments.

Communications biology| PubMed ID: 35075254

2022
RAB27A-mediated melanoma exosomes: promoters of invasion and metastasis.

Translational cancer research| PubMed ID: 35116811

2019
2022
2022